Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategic Initiatives
PFE logo

Pfizer Pivots to Oncology with $44 Billion Seagen Deal and 12 Billion-Dollar Products

PFE10-KFiling Date: 2/26/2026
Pfizer Inc.
Description

What this story covers

Pfizer is navigating post-pandemic revenue shifts by aggressively expanding into oncology and obesity through major acquisitions. Despite pricing pressures from the Inflation Reduction Act and upcoming patent cliffs, the company is targeting 5.7 billion dollars in cost savings by 2026.

Story snapshot

CompanyPfizer Inc.
TickerPFE
VariantStandard detailed
Duration13:51
Filing type10-K
PeriodAnnual 2025
IndustryHealthcare & Pharmaceuticals
Accession0000078003-26-000026
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-KView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in